BioPept Solutions: Peptide Innovation for Advanced Cosmeceutical Applications.

• Grant number: 24/09766-0
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: August 01, 2025
• End date: April 30, 2026
• Field of knowledge: Biological Sciences - Biochemistry
• Principal Investigator: Laertty Garcia de Sousa Cabral
• Grantee: Laertty Garcia de Sousa Cabral
• Associated researchers: Durvanei Augusto Maria ; Jean-Luc Poyet

Abstract

The global and Brazilian cosmetics market has experienced significant growth, with the beauty industry reaching a revenue volume of approximately US$504 billion in 2022, driven by the growing demand for beauty and personal care products, product innovations and increased awareness of skin health and well-being. In Brazil, the Beauty and Health market is expected to generate approximately US$26 billion annually, positioning the country as the 4th largest consumer market for beauty products in the world, with a market share of 48% in Latin America. In this context, our project aims to evaluate 9 innovative peptides for cosmeceutical applications, exploring their capacity for collagen biostimulation, protection of the extracellular matrix, modulation of enzymes and key receptors to combat signs of aging and promote healthy and improved skin appearance. The project methodology includes the synthesis and characterization of the peptides, in silico tests to evaluate the interaction with specific targets (molecular docking and molecular dynamics), in vitro studies to determine the efficacy and safety of the peptides in humanized skin models and isolated cell cultures, and eventually clinical tests to validate the applicability of the peptides in cosmetic formulations. In silico studies demonstrate that these peptides have the potential to interact with several key receptors and enzymes in the skin, offering multiple benefits, such as stimulation of collagen synthesis by the Insulin-Like Growth Factor Receptor I (IGF-1R), promotion of cell proliferation and tissue repair by the Epidermal Growth Factor Receptor (EGFR/erbB1), improvement of collagen synthesis and skin elasticity by modulation of Fibroblast Activation Proteins (FAPs) Alpha and Beta, protection against collagen degradation by modulation of Matrix Metalloproteinases (MMPs) and maintenance of skin integrity and firmness by inhibition of enzymes such as Leukocyte Elastase, Matriptase, Calpain I, Plasminogen and Serine 6 Transmembrane Protease. With more than 80 molecules currently undergoing in silico testing, our group demonstrates a remarkable ability to identify and develop compounds with promising properties for applications in skin care and beauty. This vast library of molecules positions us at the forefront of research and development, allowing us to explore a variety of mechanisms of action and therapeutic targets. Expected outcomes include the development of peptides with proven properties for skin rejuvenation and protection, which can be incorporated into innovative cosmetic products. The intention is to create a multifunctional product that offers superior results without the need for multiple application steps, reducing the typical skincare regimen that currently can include 3 to 5 steps. These products are expected to stand out in the market due to their solid scientific basis and proven efficacy. The impact on the company's business and the market is potentially significant, as innovation in peptides for cosmeceutical applications meets the growing consumer demands for technologically advanced and effective beauty products. In addition, leadership in the development of cutting-edge technologies for the cosmeceutical sector can position the company as a reference in the market, paving the way for strategic partnerships and expansion opportunities. (AU)